Status:
COMPLETED
Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass
Lead Sponsor:
Orion Corporation, Orion Pharma
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.
Detailed Description
Levosimendan or placebo infusion is started at the time of induction of anesthesia.
Eligibility Criteria
Inclusion
- Three vessel coronary artery disease.
- Indication for on-pump coronary artery bypass surgery.
- Ejection fraction below 50%
Exclusion
- Indication for any cardiac valve surgery
- Previous coronary artery bypass surgery
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00130871
Start Date
January 1 2004
End Date
January 1 2006
Last Update
February 21 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Central Hospital
Helsinki, Finland, 00290
2
Turku University Central Hospital
Turku, Finland